Keyphrases
5-fluorouracil (5-FU)
34%
Acute Myeloid Leukemia
35%
Adult Patients
26%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
57%
Anemia
24%
Bone Marrow
26%
Bortezomib
36%
CD34+
32%
Cell-conditioned Medium
21%
Chemotherapy
68%
Chronic Myeloid Leukemia
56%
Cisplatin
57%
Combination Chemotherapy
26%
Complete Response
19%
Confidence Interval
28%
Diffuse Large B-cell Lymphoma (DLBCL)
37%
Epirubicin
31%
Etoposide
20%
Extranodal
29%
Human Embryonic Stem Cells (hESCs)
21%
Human Mesenchymal Stem Cells (hMSCs)
31%
Human Placenta
37%
Human Pluripotent Stem Cells (hPSCs)
53%
Imatinib Mesylate
22%
Induced Pluripotent Stem Cells (iPSCs)
50%
Leucovorin
41%
Leukemia Patients
26%
Lymphoma
22%
Lymphoma Patients
28%
Mammalian Target of Rapamycin (mTOR)
19%
Mesenchymal Stem Cells
26%
Multiple Myeloma
91%
Multiple Myeloma Patients
32%
Myelodysplastic Syndrome
30%
Natural Killer T-cell Lymphoma
31%
Neutropenia
28%
Newly Diagnosed
34%
Overall Response Rate
20%
Overall Survival
49%
Phase II Study
26%
Placenta Cells
21%
Platelet Count
22%
Prognostic Value
20%
Programmed Death-ligand 1 (PD-L1)
23%
Progression-free Survival
19%
Risk Factors
22%
South Korea
38%
Stem Cell Lines
44%
Stem Cells
23%
Treatment Outcome
31%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Cancer
19%
Acute Lymphoblastic Leukemia
11%
Acute Myeloid Leukemia
37%
Anemia
14%
Anthracycline
17%
Aplastic Anemia
17%
Azacitidine
11%
Bortezomib
31%
Breast Carcinoma
11%
Chemotherapy
100%
Chronic Myeloid Leukemia
41%
Cisplatin
62%
Cohort Study
17%
Cyclophosphamide
18%
Cytarabine
14%
Decitabine
12%
Dexamethasone
13%
Diffuse Large B Cell Lymphoma
24%
Disease
39%
Eculizumab
11%
Epirubicin
31%
Etoposide
20%
Febrile Neutropenia
18%
Fibroblast Growth Factor 2
17%
Fluorouracil
24%
Folinic Acid
41%
Granulocyte Colony Stimulating Factor
13%
Idiopathic Thrombocytopenic Purpura
11%
Ifosfamide
13%
Imatinib
23%
Liver Cell Carcinoma
11%
Malignant Neoplasm
29%
Multiple Myeloma
62%
Myelodysplastic Syndrome
29%
Neoplasm
21%
Neutropenia
26%
Nilotinib
11%
NK T Cell Lymphoma
20%
Nonhodgkin Lymphoma
14%
Overall Survival
44%
Paclitaxel
11%
Paroxysmal Nocturnal Hemoglobinuria
11%
Phase II Trials
11%
Progression Free Survival
18%
Promyelocytic Leukemia
11%
Reactive Oxygen Metabolite
12%
Receptor
14%
Remission
15%
Stomach Carcinoma
19%
Survival Rate
13%
Medicine and Dentistry
Abdominal Cancer
24%
Acute Myeloid Leukemia
19%
Acute Promyelocytic Leukemia
11%
Allogeneic Hematopoietic Stem Cell Transplantation
12%
Anemia
15%
Aplastic Anemia
23%
Autologous Stem Cell Transplantation
24%
Biological Marker
13%
Bortezomib
19%
Chemotherapy
60%
Chronic Myelogenous Leukemia
23%
Cytomegalovirus
17%
Diffuse Large B-Cell Lymphoma
18%
Disease
25%
Feeder Cell
12%
Fibroblast Growth Factor 2
14%
Fluorouracil
11%
Folinic Acid
17%
Hematopoietic Cell
23%
Hematopoietic Stem Cell Transplantation
12%
Human Embryonic Stem Cell
11%
Human Pluripotent Stem Cell
17%
Immunoglobulin Producing Cell
15%
Induced Pluripotent Stem Cell
23%
Leukemia
17%
Leukemia Cell
13%
Long Term Survival
13%
Mesenchymal Stem Cell
14%
Messenger RNA
12%
Multiple Myeloma
86%
Multivariate Analysis
12%
Myelodysplastic Syndrome
13%
Myeloma
15%
Neoplasm
16%
Nilotinib
11%
NK T Cell Lymphoma
29%
Non-Hodgkin Lymphoma
13%
Observational Study
11%
Overall Survival
50%
Placenta
27%
Platelet
25%
Pluripotent Stem Cell Line
20%
Prognostic Factor
18%
Progression Free Survival
20%
Reactive Oxygen Species
12%
Receptor
11%
Risk Stratification
13%
Stem Cell
28%
Survival Rate
13%
Vasculotropin
23%